Johnson & Johnson (JNJ) Stock
Diversified healthcare giant with medicines devices and consumer products. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in September 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving
JNJ is getting credit for pipeline wins, but analysts still see room for the stock to slip if growth momentum cools.
- Analysts are weighing JNJ’s recent upbeat quarter against a still-cautious valuation, which can keep the stock under pressure even after solid operating results.
- Fresh company updates this week, including a new FDA approval for IMAAVY and upcoming healthcare conference appearances, add positive pipeline momentum but have not fully erased concerns about near-term upside.
- The stock is also being framed by a broader healthcare rotation, where investors are favoring companies with clearer growth catalysts and bigger rerating potential.
JNJ is getting credit for pipeline wins, but analysts still see room for the stock to slip if growth momentum cools.
- Analysts are weighing JNJ’s recent upbeat quarter against a still-cautious valuation, which can keep the stock under pressure even after solid operating results.
- Fresh company updates this week, including a new FDA approval for IMAAVY and upcoming healthcare conference appearances, add positive pipeline momentum but have not fully erased concerns about near-term upside.
- The stock is also being framed by a broader healthcare rotation, where investors are favoring companies with clearer growth catalysts and bigger rerating potential.
Sixth Month Growth Performance
When is the next earnings date for Johnson & Johnson (JNJ)?
The next earnings date for JNJ is expected on October 13, 2026, before the market opens. This report will cover Q3 2026. JNJ has historically followed a mid-October reporting pattern, so this timing is consistent with its usual schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Johnson & Johnson's stock with a target price of $226.87, indicating potential growth.
Financial Health
Johnson & Johnson is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
Johnson & Johnson's dividend yield of 1.97% is average, offering a modest return for dividend investors. If you invested $1000 you would be paid $19.70 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
